FGF23 and chronic kidney disease: The COMBINE trial compared NAM with lanthanum carbonate, and both treatments, together and separately, failed to significantly reduce serum phosphate or FGF23 in patients with stage 3–4 CKD over a 1-year period, likely due to limited adherence because of gastrointestinal symptoms [191].